Literature DB >> 28691507

Genetic Basis of Positive and Negative Symptom Domains in Schizophrenia.

Rose Mary Xavier1, Allison Vorderstrasse2.   

Abstract

Schizophrenia is a highly heritable disorder, the genetic etiology of which has been well established. Yet despite significant advances in genetics research, the pathophysiological mechanisms of this disorder largely remain unknown. This gap has been attributed to the complexity of the polygenic disorder, which has a heterogeneous clinical profile. Examining the genetic basis of schizophrenia subphenotypes, such as those based on particular symptoms, is thus a useful strategy for decoding the underlying mechanisms. This review of literature examines the recent advances (from 2011) in genetic exploration of positive and negative symptoms in schizophrenia. We searched electronic databases PubMed, Web of Science, and Cumulative Index to Nursing and Allied Health Literature using key words schizophrenia, symptoms, positive symptoms, negative symptoms, cognition, genetics, genes, genetic predisposition, and genotype in various combinations. We identified 115 articles, which are included in the review. Evidence from these studies, most of which are genetic association studies, identifies shared and unique gene associations for the symptom domains. Genes associated with neurotransmitter systems and neuronal development/maintenance primarily constitute the shared associations. Needed are studies that examine the genetic basis of specific symptoms within the broader domains in addition to functional mechanisms. Such investigations are critical to developing precision treatment and care for individuals afflicted with schizophrenia.

Entities:  

Keywords:  genetics; negative symptoms; positive symptoms; schizophrenia

Mesh:

Year:  2017        PMID: 28691507     DOI: 10.1177/1099800417715907

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  6 in total

1.  Treatment Capacity and Clinical Outcomes for Patients With Schizophrenia Who Were Treated With Electroconvulsive Therapy: A Retrospective Cohort Study.

Authors:  Joanne E Plahouras; Gerasimos Konstantinou; Tyler S Kaster; Daniel Z Buchman; George Foussias; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

2.  The Latent Structure of Negative Symptoms in the General Population in Adolescence and Emerging Adulthood.

Authors:  Laura Havers; Alastair Cardno; Daniel Freeman; Angelica Ronald
Journal:  Schizophr Bull Open       Date:  2022-01-12

3.  Why does age of onset predict clinical severity in schizophrenia? A multiplex extended pedigree study.

Authors:  Christie W Musket; Susan S Kuo; Petra E Rupert; Laura Almasy; Ruben C Gur; Konasale Prasad; Joel Wood; David R Roalf; Raquel E Gur; Vishwajit L Nimgaonkar; Michael F Pogue-Geile
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2020-08-19       Impact factor: 3.568

4.  Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics.

Authors:  Antonio Rampino; Silvia Torretta; Barbara Gelao; Federica Veneziani; Matteo Iacoviello; Aleksandra Marakhovskaya; Rita Masellis; Ileana Andriola; Leonardo Sportelli; Giulio Pergola; Alessandra Minelli; Chiara Magri; Massimo Gennarelli; Antonio Vita; Jean Martin Beaulieu; Alessandro Bertolino; Giuseppe Blasi
Journal:  Eur Psychiatry       Date:  2021-04-19       Impact factor: 5.361

5.  Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia.

Authors:  Rose Mary Xavier; Jennifer R Dungan; Richard S E Keefe; Allison Vorderstrasse
Journal:  Schizophr Res Cogn       Date:  2018-01-28

Review 6.  A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits.

Authors:  Tesfa Dejenie Habtewold; Lyan H Rodijk; Edith J Liemburg; Grigory Sidorenkov; H Marike Boezen; Richard Bruggeman; Behrooz Z Alizadeh
Journal:  Transl Psychiatry       Date:  2020-07-21       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.